Abstract: Methods, systems, and computer-readable storage media for receiving, through a set of user interfaces (UIs), user input including job configuration information and deployment information for an application, providing a CI/CD job for the application with a CI/CD service using the job configuration information and the deployment information, and triggering, in response to a commit of changes to the application in a repository, automated build of the application, and in response, automatically: generating a development descriptor file at least partially based on the user input, providing an archive file including the development descriptor file, and processing, by the CI/CD job executed by the CI/CD service, the archive file to deploy the application within the target environment.

Abstract: A chair frame and a casual chair are provided. The chair frame includes a frame mechanism, a connecting rod system and a seat mechanism. The connecting rod system includes a basic component fixed to the frame mechanism; a first front arm pivotally connected to the basic component; a first rear arm pivotally connected to the basic component; a first transverse arm pivotally connected to the first front arm and the first rear arm; a second transverse arm pivotally connected to the first front arm; a second rear arm pivotally connected to the first rear arm and the second transverse arm; a second front arm pivotally connected to the second transverse arm; and a lifting component pivotally connected to the second front arm and the second rear arm. The seat mechanism includes a hip-leg supporting component, a front rocker arm and a rear rocker arm.

Abstract: Disclosed are a compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, and an intermediate thereof, and the use thereof in AR or AR splicing mutant-related diseases such as cancer.

Abstract: A seat frame and a seat with switchable sitting and lying positions are provided. The seat frame includes a frame, a seat cushion, and a backrest connecting rod mechanism with a polygonal planar structure, the polygonal planar structure includes a front swing arm, a back pole frame, and a T-shaped connecting rod. A front end of the back pole frame is hinged to the upper end of the front swing arm. The T-shaped connecting rod includes two straight rods; an end of one of the two straight rods is defined as a first protruding end hinged to the lower end of the front swing arm, an end of the other of the two straight rods is defined as a second protruding end hinged to a back end of the back pole frame.

Abstract: Provided are a box of a battery, a battery, a power consumption apparatus, and a method and apparatus for producing a battery. The box includes: an electrical chamber configured to accommodate a battery cell, a pressure relief mechanism being disposed on a first wall of the battery cell, and the pressure relief mechanism being configured to be actuated when an internal pressure or temperature of the battery cell reaches a threshold, to relieve the internal pressure; a collecting chamber configured to collect emissions from the battery cell when the pressure relief mechanism is actuated, the collecting chamber being isolated from the electrical chamber; and a first thermal management component configured to accommodate a fluid to adjust a temperature of the battery cell, the first thermal management component being attached to a second wall of the battery cell, and the second wall being different from the first wall.

Abstract: The present invention relates to a flavor nanoemulsion comprising a surfactant system comprising a polyoxyethylene sorbitan fatty acid ester and a polyglycerol ester of fatty acids (PGE), a non-polar phase comprising a flavor oil, and a polar phase. The invention further relates to a flavored beverage comprising the flavor nanoemulsion according to the invention.

Abstract: The present application relates to a pyrimidopyran compound, and specifically discloses a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof.

Abstract: Provided are a battery, an electric apparatus, a method for preparing battery, and an apparatus for preparing battery. The battery includes: a plurality of battery cells, including first battery cells and second battery cells, where a pressure relief mechanism is provided on both a first wall of the first battery cell and a second wall of the second battery cell; and a thermal management component, configured to accommodate fluid to regulate temperatures of the plurality of battery cells, where the thermal management component is attached to the first wall of the first battery cell and a first wall of the second battery cell, and is provided with a pressure relief region at a position corresponding to the pressure relief mechanism of the first battery cell, to discharge emissions from the first battery cell when the pressure relief mechanism of the first battery cell is actuated.

Abstract: Disclosed are an electric wheel assembly applicable for a parallelly mounted dual-tire wheel, an axle, and a vehicle. The electric wheel assembly includes a wheel and support axle assembly, an internal-rotor hub motor, a planetary gear reducer and a brake system. A planetary carrier is connected to a hub. The hub is connected to a spoke and a rim. The wheel support axle passes through a rotor sleeve and is provided with a hub bearing to support the hub and a whole wheel. A sun gear disposed at an end of the rotor sleeve of the internal-rotor hub motor is a power input of the planetary gear speed reducer, and the planetary carrier is a power output. A planetary gear of the planetary gear reducer is a tower-shaped gear and realizes a relatively high transmission ratio under a condition that an axial length is relatively small.

Abstract: A method for diagnosing degradation of a fuel cell stack, including: S10, qualitatively determining a degradation type of the fuel cell stack according to a voltage-current curve of the fuel cell stack; S20, quantitatively measuring parameter values of each of individual cells of the fuel cell stack according to the degradation type, and quantitatively determining a degradation degree of each of the individual cells according to the parameter values; S30, determining a uniformity degradation degree among the individual cells of the fuel cell stack according to a non-uniformity degree of a voltage distribution of the individual cells. By qualitatively determining the degradation type of the fuel cell stack, the degradation condition of the entire fuel cell stack may be obtained.

Abstract: A low-floor electric axle assembly including: an axle housing, two hub motors, two planetary gear reducers, two hubs, a brake system, two C-shaped beams, and a suspension system. Mechanical mounting of the suspension system is compatible with a conventional axle. The axle housing has a left and right symmetrical dumbbell-shaped structure configured to bear a weight of a vehicle. The hub motors are inner rotor type motors and are separately arranged at two ends of the axle housing left and right symmetrically. The hub motors are arranged coaxially with two wheels respectively. Two hub motor rotors are connected to the planetary gear reducers respectively. Each of the planetary gear reducers is a single-stage planetary gear reducer. A sun gear of each of the planetary gear reducers receives power outputted by each of the hub motor. Two planetary gear reducer housings are power output ends connected to two rims respectively.

Abstract: The present invention provides for compounds of Formula (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Abstract: Disclosed are a pyrrolopyrimidine compound and a use thereof in preparing a medicine for diseases related to a BTK protein kinase inhibitor. Specially, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.

Abstract: A loading/unloading system for a quay type full-automatic container terminal includes a plurality of shore cranes, an operation lane area between two rails of the shore cranes, an operation area from a rear side of a landside rail of the shore cranes to a yard, an automatic container yard area, an operation lane area of the yard, and facilities behind the yard. The shore cranes are disposed in parallel at a front edge of a container terminal to autonomously complete shipping and unshipping operations of containers, and autonomously complete loading/unloading processes of artificial intelligence transportation robots through information interaction with an artificial intelligence transportation robot system. The operation lane area between two rails of the shore cranes includes: a lambdoidal reverse operation area of inner container trucks, a ship lofting operation area, and a loading/unloading operation area of the inner container trucks, which are physically isolated by fences.

Abstract: The disclosure provides an intelligent horizontal transportation system for a completely automatic side-loading/unloading container terminal. The system includes a horizontal transportation device including an unmanned artificial intelligence robot of transportation (ART) and a horizontal transportation control system that intelligently manages and controls the ART to enable it to complete horizontal transportation. The horizontal transportation control system is in real-time connection and communication with a terminal operation system (TOS), an automatic field crane, an automatic shore crane and the ART to complete information interactive processing to realize information interconnection, so as to guarantee real-time utilization of information and intelligent control of the ART. The horizontal transportation control system realizes intelligent management and control of the horizontal transportation device by executing the following functions.

Abstract: Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides for compounds of Formula (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Abstract: A multi-environment integrative thermal management method for a fuel cell vehicle is provided. The method can ensure the accuracy and the stability of the control for a temperature of a fuel cell system of the fuel cell vehicle in a complicated and changeable environment, decrease the energy consumption of the entire vehicle, and increase the economical efficiency of the entire vehicle.

Abstract: Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.

Abstract: A multi-environment integrative thermal management method for a fuel cell vehicle is provided. The method can ensure the accuracy and the stability of the control for a temperature of a fuel cell system of the fuel cell vehicle in a complicated and changeable environment, decrease the energy consumption of the entire vehicle, and increase the economical efficiency of the entire vehicle.